PR Newswire Clinical TrialsOriginal article
Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds
Phase 1positiveBisphosphocin® Nu-8Positive
AI Analysis
Summary
Lakewood-Amedex Biotherapeutics announced positive preclinical data showing Bisphosphocin® Nu-8 achieved up to 97% inhibition of E. coli growth in rodent models of urinary tract and pulmonary infections when administered intravesically.
Clinical Trial Data
Phase
preclinical
Primary Endpoint
Met
Outcome Details
Intravesical administration of Bisphosphocin® Nu-8 to rodents infected with E. coli demonstrated up to 97% inhibition of E. coli growth compared to no effect in vehicle control group
Importance:3/10
Sentiment:
0.70
preclinical dataurinary tract infectionpulmonary infectionE. colibisphosphocin
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on October 7, 2026 12:02 PM